342 related articles for article (PubMed ID: 14647331)
1. Approaches for the sequence-specific knockdown of mRNA.
Scherer LJ; Rossi JJ
Nat Biotechnol; 2003 Dec; 21(12):1457-65. PubMed ID: 14647331
[TBL] [Abstract][Full Text] [Related]
2. RNA interference detected 20 years ago?
Schmidt FR
Nat Biotechnol; 2004 Mar; 22(3):267-8. PubMed ID: 14990942
[No Abstract] [Full Text] [Related]
3. Tomato transgene structure and silencing.
Sanders RA; Hiatt W
Nat Biotechnol; 2005 Mar; 23(3):287-9. PubMed ID: 15765076
[No Abstract] [Full Text] [Related]
4. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
Mahato RI; Cheng K; Guntaka RV
Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
[TBL] [Abstract][Full Text] [Related]
5. Anti-genes: siRNA, ribozymes and antisense.
Scanlon KJ
Curr Pharm Biotechnol; 2004 Oct; 5(5):415-20. PubMed ID: 15544489
[TBL] [Abstract][Full Text] [Related]
6. Antisense technology: a selective tool for gene expression regulation and gene targeting.
Sahu NK; Shilakari G; Nayak A; Kohli DV
Curr Pharm Biotechnol; 2007 Oct; 8(5):291-304. PubMed ID: 17979727
[TBL] [Abstract][Full Text] [Related]
7. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes.
Fokina AA; Stetsenko DA; François JC
Expert Opin Biol Ther; 2015 May; 15(5):689-711. PubMed ID: 25772532
[TBL] [Abstract][Full Text] [Related]
8. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming.
Saetrom P
Bioinformatics; 2004 Nov; 20(17):3055-63. PubMed ID: 15201190
[TBL] [Abstract][Full Text] [Related]
9. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies.
Khan A; Benboubetra M; Sayyed PZ; Ng KW; Fox S; Beck G; Benter IF; Akhtar S
J Drug Target; 2004 Jul; 12(6):393-404. PubMed ID: 15545089
[TBL] [Abstract][Full Text] [Related]
10. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells.
Miyagishi M; Hayashi M; Taira K
Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):1-7. PubMed ID: 12691531
[TBL] [Abstract][Full Text] [Related]
12. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing.
Harborth J; Elbashir SM; Vandenburgh K; Manninga H; Scaringe SA; Weber K; Tuschl T
Antisense Nucleic Acid Drug Dev; 2003 Apr; 13(2):83-105. PubMed ID: 12804036
[TBL] [Abstract][Full Text] [Related]
13. Spiegelzymes® mirror-image hammerhead ribozymes and mirror-image DNAzymes, an alternative to siRNAs and microRNAs to cleave mRNAs in vivo?
Wyszko E; Mueller F; Gabryelska M; Bondzio A; Popenda M; Barciszewski J; Erdmann VA
PLoS One; 2014; 9(1):e86673. PubMed ID: 24489764
[TBL] [Abstract][Full Text] [Related]
14. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
15. Applications of nucleic acid technology in the CNS.
Trülzsch B; Wood M
J Neurochem; 2004 Jan; 88(2):257-65. PubMed ID: 14690514
[TBL] [Abstract][Full Text] [Related]
16. Native mRNA antisense-accessible sites library for the selection of antisense oligonucleotides, PNAs, and siRNAs.
Fang H; Shen Y; Taylor JS
RNA; 2010 Jul; 16(7):1429-35. PubMed ID: 20498459
[TBL] [Abstract][Full Text] [Related]
17. Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition.
Pierce ML; Ruffner DE
Nucleic Acids Res; 1998 Nov; 26(22):5093-101. PubMed ID: 9801305
[TBL] [Abstract][Full Text] [Related]
18. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.
Beale G; Hollins AJ; Benboubetra M; Sohail M; Fox SP; Benter I; Akhtar S
J Drug Target; 2003 Aug; 11(7):449-56. PubMed ID: 15203934
[TBL] [Abstract][Full Text] [Related]
19. Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents.
Kolniak TA; Sullivan JM
Exp Eye Res; 2011 May; 92(5):328-37. PubMed ID: 21256844
[TBL] [Abstract][Full Text] [Related]
20. Strategies to identify potential therapeutic target sites in RNA.
Lützelberger M; Kjems J
Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
